Saturday, August 19, 2017 11:51:56 AM
With regard to buying more if the phase 3 results are positive (or deciding at what price to dump the shares I hold) it's tough. I'm not convinced this stock will rocket on a successful phase 3 to the extent that many here predict. There is obviously a huge discount applied to this stock for some reason (I have my own theories about that) and I don't see why that would change. A normal company would probably see a nice bump to a multiple billion dollar mc upon successful readout. However, a normal company would also be currently valued several multiples higher than Northwest near the conclusion of a phase 3 trial. I believe diminished value would continue even with phase 3 success due to certain internal issues that will continue to drag down the company.
What if the trial is statistically significant, but OS is only extended a few months? What would that mean for health insurance reimbursement? Btw I'm not convinced ins. coverage for Keytruda, Opdivo, or other immunotherapies with minimal benefit is the right thing for our struggling health care system either..
Anyway, does one sell on a pop to $1 or $2 bucks? IMO, that may be all she's good for. Hope I'm wrong because I would love to at least break even on the pos. I'm just not convinced BP wants anything to do with this technology in terms of a buy out, even if the trial succeeds. Without BP support, does the market see this as DNDN part two and not provide Kite and Juno type euphoria? I dunno...
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM